Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cellebrite Di Ltd
(NQ:
CLBT
)
17.02
+0.25 (+1.49%)
Streaming Delayed Price
Updated: 9:44 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cellebrite Di Ltd
< Previous
1
2
Next >
H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday
August 16, 2024
Via
Benzinga
CLBT Stock Earnings: Cellebrite DI Beats EPS, Beats Revenue for Q2 2024
August 15, 2024
CLBT stock results show that Cellebrite DI beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Will The Nasdaq 100's Relief Rally Hold Or Is A Sharp Decline Inevitable?
July 24, 2024
Find out how might the rotation of funds into small-cap stocks and the Dow Jones affect the Nasdaq 100.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
FBI Reportedly Used Israel-Based Security Firm's Unreleased Technology To Crack Trump Shooter's Phone
July 19, 2024
Despite having a license for Cellebrite's software, the FBI's Pittsburgh bureau was unable to bypass the passcode on Crooks' newer Samsung model phone, which runs on Android's operating system.
Via
Benzinga
Topics
Government
Exposures
Criminal
Legal
Political
Why Software Company Cellebrite Shares Are Up Today
May 23, 2024
Cellebrite DI reported strong Q1 FY24 results with revenue up 26% YoY, ARR at $331.8 million, and EPS beating consensus. Outlook remains positive with expected revenue of $90M-$94M in Q2 and...
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Cellebrite DI: Q3 Earnings Insights
November 14, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Cellebrite DI
August 30, 2023
Via
Benzinga
CLBT Stock Earnings: Cellebrite DI Beats EPS, Beats Revenue for Q1 2024
May 23, 2024
CLBT stock results show that Cellebrite DI beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Expert Ratings for Cellebrite DI
August 09, 2023
Via
Benzinga
Preview: Cellebrite DI's Earnings
August 07, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023
July 19, 2023
Via
Benzinga
Recap: Cellebrite DI Q1 Earnings
May 10, 2023
Via
Benzinga
Earnings Preview For Cellebrite DI
November 16, 2022
Via
Benzinga
Expert Ratings for Cellebrite DI
August 12, 2022
Analysts have provided the following ratings for Cellebrite DI (NASDAQ:CLBT) within the last quarter:
Via
Benzinga
The 7 Best Stocks Under $10 to Buy in May
May 03, 2023
While quality matters in the market, these best stocks under $10 to buy gives you some potential diamonds in the rough.
Via
InvestorPlace
Major Compression Regimes In Multiple Markets…
May 01, 2023
In this week’s Dirty Dozen we cover more recession signals, bullish price action in the main markets, a big set up in the US dollar, a major compression regime in bonds, and more…
Via
Talk Markets
7 Tech Stocks to Buy for the Next Decade
March 20, 2023
While jitters abound, intrepid investors may target these compelling innovators.
Via
InvestorPlace
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
March 14, 2023
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...
Via
Benzinga
7 Tech Stocks to Snatch Out of the Bargain Bin
February 06, 2023
Although the innovation space provides several compelling opportunities, you don’t have to pay full price with these tech stock bargains.
Via
InvestorPlace
Earnings Scheduled For November 17, 2022
November 17, 2022
Companies Reporting Before The Bell • Jumia Technologies (NYSE:JMIA) is expected to report quarterly loss at $0.76 per share on revenue of $57.32 million.
Via
Benzinga
Overview Of Value Stocks In The Technology Sector
October 04, 2022
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
September 09, 2022
It's time for another deep dive into the biggest pre-market stock movers for Friday and the news that has these shares moving this morning.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
August 12, 2022
Via
Benzinga
Overview Of Value Stocks In The Technology Sector
August 02, 2022
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
5 Value Stocks To Watch In The Technology Sector
June 07, 2022
What are Value Stocks?
Via
Benzinga
Where Cellebrite DI Stands With Analysts
February 24, 2022
Cellebrite DI (NASDAQ:CLBT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
56 Biggest Movers From Yesterday
February 17, 2022
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead...
Via
Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; EIA Reports Unexpected Rise In Crude Inventories
February 16, 2022
US stocks traded lower midway through trading on Wednesday ahead of the release of Fed minutes.
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
February 16, 2022
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.